In 2012, the founding members of Softhale met and started their conceptual work on a new generation Soft Mist Inhaler (SMI). The team had proven expertise in the microfluidic, medical device, pharmaceutical, and business development competencies, and the collaboration resulted in a business concept to start a pharmaceutical company.
The first patent was filed by the group in 2013.
The team then conducted concept validation work and initial freedom-to-operate analysis, followed by the creation of a business plan. This plan – coupled with the team’s strong background – helped Softhale raise seed funding, leading to early-stage proof-of-concept work in 2014-2015.
Since then, the Softhale team has successfully expanded collaborations across geographies, attracting series of funding and investing in a proprietary, innovative approach to inhalation therapy. This led to a successful Series A round, a more than €1 million grant, and a first customer-funded proof-of-concept study in 2016.
Softhale NV was established in Diepenbeek, Belgium in 2016, and development activities related to our proprietary next-generation SMI intensified.
In 2018 and 2019, the internal team grew with the recruitment of leading industry experts in the respiratory field with a long track record of bringing inhalable branded and generic products to market.
Softhale’s proprietary device technology is protected by 15+ patents. Our portfolio also expanded with a branded high-end product. Our current activities are financed by the successful series B fundraising closed in early 2019.
Sino Biopharmaceuticals takes the main stake in Softhale NV.
Over the past years, our investors have played a fundamental role in transforming Softhale from its medical technology-driven origins into a highly specialized developer of respiratory medicines. Also, in accelerating the development of our pipeline with operational expertise, resources, and a global network they played a crucial role.
At this moment in time, at this crucial point of our development, Sino Biopharm is a great partner on our mission to further advance and broaden the development of our platform and to build and launch a new generation of highly effective inhalable medicines on a global scale.
Dr. Jan-Torsten Tews, CEO of Softhale
March 22, 2021